UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Chagas disease: Antitrypanosomal drug therapy

Author
Caryn Bern, MD, MPH
Section Editor
Peter F Weller, MD, FACP
Deputy Editor
Elinor L Baron, MD, DTMH

INTRODUCTION

Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi. Issues related to antitrypanosomal drugs will be reviewed here. The approach to management of Chagas disease varies by phase and form of disease and is discussed in detail separately (table 1). (See "Chagas disease: Management of acute disease, early chronic disease, and disease in immunosuppressed hosts".)

ANTITRYPANOSOMAL DRUGS

The only drugs with proven efficacy against Chagas disease in human trials are benznidazole and nifurtimox [1,2]. In general, benznidazole is better tolerated and so is favored by most experts as the first-line treatment for Chagas disease [3]. However, some patients tolerate nifurtimox better than benznidazole; when treatment with one drug must be discontinued, the other can be used as an alternative. Limited human data, supported by findings in animal models, suggest that T. cruzi strains may vary in their drug susceptibility [4-8].

Both benznidazole and nifurtimox are contraindicated in pregnancy, so effective contraception should be assured. In addition, both drugs demonstrate in vitro mutagenicity and have been associated with increased risk of lymphomas in experimental animals [9-12]. No increase in incidence of lymphoma has been observed among immunocompetent humans, although no long-term studies examining this issue have been conducted [13]. An increased incidence of neoplasm was reported in a small series of heart transplantation recipients for Chagas disease [14].

Antitrypanosomal agents are contraindicated in patients with severe renal or hepatic dysfunction.

Neither drug is approved in the United States, but both can be obtained from the Centers for Disease Control and Prevention (CDC) and used under investigational protocols. Consultations and drug requests should be addressed to Division of Parasitic Diseases Public Inquiries line (404-718-4745; email parasites@cdc.gov), the CDC Drug Service (404-639-3670), and, for emergencies after business hours, on weekends and federal holidays, through the CDC Emergency Operations Center (770-488-7100).

    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Oct 26 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Rodriques Coura J, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002; 97:3.
  2. Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.
  3. Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.
  4. Rassi, A, Ferreira, HO. Tentativas de tratamento especifico da fase aguda da doença de Chagas com nifurtimox em esquema de duraçao prolongada. Rev Soc Bras Med Trop 1971; 5:235.
  5. Boainain, E. Tratamento etiologico da doença de Chagas na fase cro. Rev Goiania Med 1979; 25:1.
  6. Camandaroba EL, Reis EA, Gonçalves MS, et al. Trypanosoma cruzi: susceptibility to chemotherapy with benznidazole of clones isolated from the highly resistant Colombian strain. Rev Soc Bras Med Trop 2003; 36:201.
  7. Veloso VM, Carneiro CM, Toledo MJ, et al. Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains. Mem Inst Oswaldo Cruz 2001; 96:1005.
  8. Zingales B, Miles MA, Moraes CB, et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz 2014; 0:0.
  9. Ferreira RC, Ferreira LC. Mutagenicity of nifurtimox and benznidazole in the Salmonella/microsome assay. Braz J Med Biol Res 1986; 19:19.
  10. Gorla NB, Ledesma OS, Barbieri GP, Larripa IB. Thirteenfold increase of chromosomal aberrations non-randomly distributed in chagasic children treated with nifurtimox. Mutat Res 1989; 224:263.
  11. Teixeira AR, Córdoba JC, Souto Maior I, Solórzano E. Chagas' disease: lymphoma growth in rabbits treated with Benznidazole. Am J Trop Med Hyg 1990; 43:146.
  12. Teixeira AR, Silva R, Cunha Neto E, et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes. J Comp Pathol 1990; 103:37.
  13. Kirchhoff LV. Chagas disease. American trypanosomiasis. Infect Dis Clin North Am 1993; 7:487.
  14. Bocchi EA, Higuchi ML, Vieira ML, et al. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease. J Heart Lung Transplant 1998; 17:399.
  15. US Pharmacopeial Convention. Benznidazole. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995.
  16. Miller DA, Hernandez S, Rodriguez De Armas L, et al. Tolerance of benznidazole in a United States Chagas Disease clinic. Clin Infect Dis 2015; 60:1237.
  17. Salvador F, Sánchez-Montalvá A, Martínez-Gallo M, et al. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis 2015; 61:1688.
  18. US Pharmacopeial Convention. Nifurtimox. US Pharmacopeia Monographs: US Pharmacopeial Convention, 1995.
  19. Wegner DH, Rohwedder RW. The effect of nifurtimox in acute Chagas' infection. Arzneimittelforschung 1972; 22:1624.
  20. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.
  21. Forsyth CJ, Hernandez S, Olmedo W, et al. Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States. Clin Infect Dis 2016; 63:1056.
  22. Ribeiro I, Sevcsik AM, Alves F, et al. New, improved treatments for Chagas disease: from the R&D pipeline to the patients. PLoS Negl Trop Dis 2009; 3:e484.
  23. Diniz Lde F, Caldas IS, Guedes PM, et al. Effects of ravuconazole treatment on parasite load and immune response in dogs experimentally infected with Trypanosoma cruzi. Antimicrob Agents Chemother 2010; 54:2979.
  24. Urbina JA. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 2010; 115:55.
  25. Pinazo MJ, Espinosa G, Gállego M, et al. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg 2010; 82:583.
  26. Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.
  27. Drugs for Neglected Disease Initiative. Chagas disease: DNDi Strategy, 2010. http://www.treatchagas.org/rd_dndi_strategy.aspx (Accessed on March 10, 2010).
  28. Urbina JA. New advances in the management of a long-neglected disease. Clin Infect Dis 2009; 49:1685.